Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
Latest Information Update: 27 Nov 2025
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms COMPASS-HCM
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 03 Nov 2025 According to Bristol Myers Squibb media release, data from this trial will be presented at the American Heart Association's Scientific Sessions 2025, taking place November 7-10, 2025 in New Orleans, Louisiana.
- 17 Apr 2025 According to Bristol Myers Squibb media release, the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS,The approved label update is supported by this trial.
- 16 Aug 2024 New trial record